A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

NCT ID: NCT05952856

Last Updated: 2025-09-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

2912 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-10

Study Completion Date

2025-07-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia. The primary hypothesis is that enlicitide decanoate is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolemia Familial Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Enlicitide Decanoate

Participants will receive 20 mg of enlicitide decanoate orally once daily (QD) for up to 52 weeks.

Group Type EXPERIMENTAL

Enlicitide Decanoate

Intervention Type DRUG

Oral tablet

Placebo

Participants will receive enlicitide decanoate-matching placebo orally QD for up to 52 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enlicitide Decanoate

Oral tablet

Intervention Type DRUG

Placebo

Oral tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MK-0616

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has a history of a major atherosclerotic cardiovascular disease (ASCVD) event and LDL-C ≥55 mg/dL OR, if no history of a major ASCVD event, has intermediate to high risk for development of a first major ASCVD event and LDL-C ≥70 mg/dL.
* Is treated with a moderate- or high-intensity statin OR is treated with low-intensity statin with documentation of intolerance to a moderate or high-intensity statin OR is not receiving statins with documentation of statin intolerance
* If on any lipid-lowering therapies (LLTs), should be on a stable dose with no planned medication change.

Exclusion Criteria

* Has a history of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria, compound heterozygous FH, or double heterozygous FH
* Has a history of heart failure or heart failure hospitalization within 3 months before first study visit
* Is undergoing or previously underwent an LDL-C apheresis program within 3 months before first study visit or plans to initiate an LDL-C apheresis program
* Was previously treated/is being treated with certain other cholesterol lowering medications, including protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors without adequate washout
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sheba Medical Center ( Site 1708)

Ramat Gan, , Israel

Site Status

Rambam Health Care Campus-internal department ( Site 1718)

Haifa, , Israel

Site Status

Shaare Zedek Medical Center ( Site 1710)

Jerusalem, , Israel

Site Status

Hadassah Medical Center ( Site 1706)

Jerusalem, , Israel

Site Status

Hadassah Medical Center ( Site 1709)

Jerusalem, , Israel

Site Status

Meir Medical Center. ( Site 1714)

Kfar Saba, , Israel

Site Status

Rabin Medical Center ( Site 1720)

Petah Tikva, , Israel

Site Status

Alliance for Multispecialty Research, LLC ( Site 0093)

Daphne, Alabama, United States

Site Status

G&L Research ( Site 0043)

Foley, Alabama, United States

Site Status

Synexus Clinical Research US, Inc.-Synexus Clinical Research US, Inc - Central Phoenix ( Site 0084)

Phoenix, Arizona, United States

Site Status

National Heart Institute-Research ( Site 0087)

Beverly Hills, California, United States

Site Status

Clinical Trials Research ( Site 0115)

Sacramento, California, United States

Site Status

Velocity Clinical Research, Banning ( Site 0017)

San Bernardino, California, United States

Site Status

Emerson Clinical Research Institute ( Site 0118)

Washington D.C., District of Columbia, United States

Site Status

Excel Medical Clinical Trials ( Site 0053)

Boca Raton, Florida, United States

Site Status

Alliance for Multispecialty Research, LLC ( Site 0088)

Coral Gables, Florida, United States

Site Status

Alliance for Multispecialty Research, LLC ( Site 0094)

Fort Myers, Florida, United States

Site Status

Velocity Clinical Research, Hallandale Beach ( Site 0018)

Hallandale, Florida, United States

Site Status

Jacksonville Center for Clinical Research ( Site 0049)

Jacksonville, Florida, United States

Site Status

South Broward Research ( Site 0051)

Miramar, Florida, United States

Site Status

Clinical Research Trials of Florida ( Site 0063)

Tampa, Florida, United States

Site Status

East Coast Institute for Research, LLC ( Site 0033)

Macon, Georgia, United States

Site Status

Healthcare Research Network - Chicago ( Site 0052)

Flossmoor, Illinois, United States

Site Status

Synexus Clinical Research US, Inc. ( Site 0109)

Evansville, Indiana, United States

Site Status

Midwest Institute For Clinical Research ( Site 0059)

Indianapolis, Indiana, United States

Site Status

Alliance for Multispecialty Research, LLC ( Site 0028)

Lexington, Kentucky, United States

Site Status

L-MARC Research Center ( Site 0001)

Louisville, Kentucky, United States

Site Status

Velocity Clinical Research, Covington ( Site 0068)

Covington, Louisiana, United States

Site Status

Velocity Clinical Research Rockville ( Site 0082)

Rockville, Maryland, United States

Site Status

Velocity Clinical Research, Gulfport ( Site 0039)

Gulfport, Mississippi, United States

Site Status

Healthcare Research Network - St. Louis ( Site 0054)

Hazelwood, Missouri, United States

Site Status

Jubilee Clinical Research ( Site 0106)

Las Vegas, Nevada, United States

Site Status

AB Clinical Trials ( Site 0070)

Las Vegas, Nevada, United States

Site Status

New Mexico Clinical Research & Osteoporosis Center ( Site 0005)

Albuquerque, New Mexico, United States

Site Status

Velocity Clinical Research, Syracuse ( Site 0021)

East Syracuse, New York, United States

Site Status

Icahn School of Medicine at Mount Sinai-Cardiology ( Site 0002)

New York, New York, United States

Site Status

Lillestol Research ( Site 0026)

Fargo, North Dakota, United States

Site Status

altoona center for clinical research ( Site 0089)

Duncansville, Pennsylvania, United States

Site Status

Cardiology Consultants of Philadelphia Yardley ( Site 0097)

Yardley, Pennsylvania, United States

Site Status

Piedmont Research Partners ( Site 0090)

Fort Mill, South Carolina, United States

Site Status

Velocity Clinical Research, Greenville ( Site 0023)

Greenville, South Carolina, United States

Site Status

Coastal Carolina Research Center ( Site 0006)

North Charleston, South Carolina, United States

Site Status

Monument Health Clinical Research, a department of Monument -Monument Health Clinical Research, a d ( Site 0009)

Rapid City, South Dakota, United States

Site Status

Holston Medical Group ( Site 0048)

Kingsport, Tennessee, United States

Site Status

Alliance for Multispecialty Research, LLC ( Site 0008)

Knoxville, Tennessee, United States

Site Status

Velocity Clinical Research, Dallas ( Site 0114)

Dallas, Texas, United States

Site Status

Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0111)

Houston, Texas, United States

Site Status

Clinical Trials of Texas, LLC ( Site 0103)

San Antonio, Texas, United States

Site Status

Synexus Clinical Research US, Inc. ( Site 0110)

Salt Lake City, Utah, United States

Site Status

Velocity Clinical Research, Salt Lake City ( Site 0019)

West Jordan, Utah, United States

Site Status

Manassas Clinical Research Center ( Site 0007)

Manassas, Virginia, United States

Site Status

Health Research of Hampton Roads, Inc. ( Site 0044)

Newport News, Virginia, United States

Site Status

Alliance for Multispecialty Research, LLC ( Site 0101)

Norfolk, Virginia, United States

Site Status

National Clinical Research, Inc ( Site 0061)

Richmond, Virginia, United States

Site Status

Centricity Research Suffolk Family Medicine ( Site 0092)

Suffolk, Virginia, United States

Site Status

Rainier Clinical Research Center ( Site 0116)

Renton, Washington, United States

Site Status

CEDIC ( Site 0612)

CABA, Buenos Aires, Argentina

Site Status

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0605)

Mar del Plata, Buenos Aires, Argentina

Site Status

Instituto de Investigaciones Clinicas Zarate ( Site 0600)

Zárate, Buenos Aires, Argentina

Site Status

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada ( Site 0604)

Buenos Aires, Buenos Aires F.D., Argentina

Site Status

Fundación Respirar ( Site 0610)

Buenos Aires, Buenos Aires F.D., Argentina

Site Status

Centro de Investigaciones Metabólicas (CINME)-Cardiology ( Site 0620)

CABA, , Argentina

Site Status

Beijing Anzhen Hospital, Capital Medical University-Cardiovascular ( Site 3300)

Beijing, Beijing Municipality, China

Site Status

Beijing Friendship Hospital Affiliate of Capital University-Cardiology ( Site 3303)

Beijing, Beijing Municipality, China

Site Status

The Second Affiliated Hospital of Chongqing Medical University ( Site 3320)

Chongqing, Chongqing Municipality, China

Site Status

Chongqing University Three Gorges Hospital ( Site 3321)

Chongqing, Chongqing Municipality, China

Site Status

Guangdong Provincial People's Hospital-Cardiology ( Site 3304)

Guangzhou, Guangdong, China

Site Status

Zhujiang Hospital of Southern Medical University ( Site 3329)

Guangzhou, Guangdong, China

Site Status

Huizhou Municipal Central Hospital ( Site 3379)

Huizhou, Guangdong, China

Site Status

The University of Hong Kong-Shenzhen Hospital-Cardiovascular department ( Site 3318)

Shenzhen, Guangdong, China

Site Status

Jingzhou Central Hospital-Cardiology ( Site 3376)

Jingzhou, Hubei, China

Site Status

Wuhan Fourth Hospital ( Site 3356)

Wuhan, Hubei, China

Site Status

Hunan Provincial People's Hospital-Cardiology ( Site 3317)

Changsha, Hunan, China

Site Status

Changzhou Second People's Hospital-Cardiology ( Site 3373)

Changzhou, Jiangsu, China

Site Status

Northern Jiangsu People's Hospital ( Site 3308)

Yangzhou, Jiangsu, China

Site Status

The Third Hospital of Nanchang - Fuhe-cardiology ( Site 3378)

Nanchang, Jiangxi, China

Site Status

Siping Central People's Hospital-Cardiovascular Department ( Site 3311)

Siping, Jilin, China

Site Status

Xianyang Hospital of Yan'an University ( Site 3340)

Xianyang, Shaanxi, China

Site Status

Chengdu Second Municipal People's Hospital ( Site 3332)

Chengdu, Sichuan, China

Site Status

People's Hospital of Lishui City-department of cardiovascular ( Site 3302)

Lishui, Zhejiang, China

Site Status

Fundación Centro de Investigación Clínica CIC ( Site 0906)

Medellín, Antioquia, Colombia

Site Status

Ciensalud Ips S A S ( Site 0903)

Barranquilla, Atlántico, Colombia

Site Status

Clinica de la Costa S.A.S. ( Site 0902)

Barranquilla, Atlántico, Colombia

Site Status

Salud SURA Calle 100 ( Site 0918)

Bogotá, Cundinamarca, Colombia

Site Status

Healthy Medical Center S.A.S ( Site 0913)

Zipaquirá, Cundinamarca, Colombia

Site Status

Fundación Valle del Lili ( Site 0904)

Cali, Valle del Cauca Department, Colombia

Site Status

Unterfrintroper Hausarztzentrum Klinische Forschung ( Site 1542)

Essen, North Rhine-Westphalia, Germany

Site Status

Universitaetsklinikum Carl Gustav Carus Dresden-Universitätsstudienzentrum für Stoffwechselerkranku ( Site 1508)

Dresden, Saxony, Germany

Site Status

Hausarzt- und Diabetologische Schwerpunktpraxis Hohenmölsen - Weiβenfels ( Site 1527)

Hohenmölsen, Saxony-Anhalt, Germany

Site Status

Zentralklinik Bad Berka ( Site 1530)

Bad Berka, Thuringia, Germany

Site Status

Velocity Clinical Research GmbH Berlin ( Site 1502)

Berlin, , Germany

Site Status

Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1533)

Berlin, , Germany

Site Status

Hillel Yaffe Medical Center ( Site 1705)

Hadera, , Israel

Site Status

Yitzhak Shamir Medical Center. ( Site 1712)

Ẕerifin, , Israel

Site Status

Fondazione Policlinico Tor Vergata ( Site 1809)

Rome, Lazio, Italy

Site Status

Centro Cardiologico Monzino ( Site 1804)

Milan, Milano, Italy

Site Status

ASST Grande Ospedale Metropolitano Niguarda-Unità Ricerche Cliniche della Cardiologia 4 ( Site 1811)

Milan, Milano, Italy

Site Status

Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino ( Site 1801)

Turin, Piedmont, Italy

Site Status

Azienda Ospedaliera Sant'Andrea-Department of Clinical and Molecular Medicine ( Site 1807)

Rome, Roma, Italy

Site Status

Azienda Ospedaliera Garibaldi ( Site 1810)

Catania, , Italy

Site Status

Hirohata Naika Clinic ( Site 3513)

Kitakyusyu-shi, Fukuoka, Japan

Site Status

Nakakinen clinic ( Site 3510)

Naka, Ibaraki, Japan

Site Status

Noritake Clinic ( Site 3512)

Ushiku, Ibaraki, Japan

Site Status

National Hospital Organization Kanazawa Medical Center ( Site 3508)

Kanazawa, Ishikawa-ken, Japan

Site Status

Hirano Medical Clinic ( Site 3522)

Morioka, Iwate, Japan

Site Status

Shirai Healthcare Clinic Izumichuou ( Site 3527)

Sendai, Miyagi, Japan

Site Status

Rinku General Medical Center ( Site 3503)

Izumisano, Osaka, Japan

Site Status

Shiraiwa Medical Clinic ( Site 3514)

Kashihara, Osaka, Japan

Site Status

Medical Corporation Heishinkai OCROM Clinic ( Site 3501)

Suita-shi, Osaka, Japan

Site Status

Saitama Medical University Hospital ( Site 3506)

Iruma, Saitama, Japan

Site Status

Teramoto Medical and Dental Clinic ( Site 3507)

Bunkyo-ku, Tokyo, Japan

Site Status

Tokyo-Eki Center-building Clinic ( Site 3505)

Chuo-ku, Tokyo, Japan

Site Status

Fukuwa Clinic ( Site 3504)

Chuo-ku, Tokyo, Japan

Site Status

Teikyo University Hospital ( Site 3500)

Itabashi-ku, Tokyo, Japan

Site Status

Kato Clinic of Internal Medicine ( Site 3509)

Katsushika-ku, Tokyo, Japan

Site Status

Kanno Naika ( Site 3511)

Mitaka, Tokyo, Japan

Site Status

Sugawara Clinic ( Site 3519)

Nerima-ku, Tokyo, Japan

Site Status

Shin Clinic ( Site 3517)

Ōta-ku, Tokyo, Japan

Site Status

Medical Corporation Heishinkai ToCROM Clinic ( Site 3502)

Shinjuku-ku, Tokyo, Japan

Site Status

Mitsukoshi Health and Welfare Foundation ( Site 3521)

Shinjuku-ku, Tokyo, Japan

Site Status

Medical Corporation Hakuaikai Wellness Tenjin Clinic ( Site 3520)

Fukuoka, , Japan

Site Status

Hiroshima City Hiroshima Citizens Hospital ( Site 3518)

Hiroshima, , Japan

Site Status

Mishuku Hospital ( Site 3524)

Tokyo, , Japan

Site Status

Instituto Jalisciense de Investigacion en Diabetes y Obesidad-Endocrinology ( Site 1057)

Guadalajara, Jalisco, Mexico

Site Status

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 1071)

Mexico City, Mexico City, Mexico

Site Status

IATROS INTERNATIONAL ( Site 2247)

Bloemfontein, Free State, South Africa

Site Status

Soweto Clinical Trials Centre ( Site 2242)

Johannesburg, Gauteng, South Africa

Site Status

Charlotte Maxeke Johannesburg Academic Hospital-WCR-LIPIDS ( Site 2241)

Johannesburg, Gauteng, South Africa

Site Status

Tiervlei Trial Centre-Clinical ( Site 2246)

Bellville, Cape Town, Western Cape, South Africa

Site Status

TREAD Research ( Site 2253)

Cape Town, Western Cape, South Africa

Site Status

University of Cape Town (UCT)-Medicine, Division of Lipidology ( Site 2259)

Cape Town, Western Cape, South Africa

Site Status

Wonju Severance Christian Hospital ( Site 3008)

Wŏnju, Kang-won-do, South Korea

Site Status

Chonnam National University Hospital ( Site 3014)

Gwangju, Kwangju-Kwangyokshi, South Korea

Site Status

Seoul National University Bundang Hospital ( Site 3005)

Seongnam, Kyonggi-do, South Korea

Site Status

Ajou University Hospital ( Site 3006)

Suwon, Kyonggi-do, South Korea

Site Status

Chungbuk National University Hospital ( Site 3011)

Cheongju-si, North Chungcheong, South Korea

Site Status

Dong-A University Hospital ( Site 3013)

Busan, Pusan-Kwangyokshi, South Korea

Site Status

Pusan National University Hospital-Internal Medicine ( Site 3012)

Busan, Pusan-Kwangyokshi, South Korea

Site Status

Inje University Haeundae Paik Hospital ( Site 3010)

Haeundae-gu, Pusan-Kwangyokshi, South Korea

Site Status

Keimyung University Dongsan Hospital CRC room 1 ( Site 3003)

Daegu, Taegu-Kwangyokshi, South Korea

Site Status

Seoul National University Hospital ( Site 3001)

Seoul, , South Korea

Site Status

Kangbuk Samsung Hospital ( Site 3009)

Seoul, , South Korea

Site Status

Severance Hospital, Yonsei University Health System ( Site 3002)

Seoul, , South Korea

Site Status

Asan Medical Center ( Site 3004)

Seoul, , South Korea

Site Status

Samsung Medical Center-cardiology ( Site 3000)

Seoul, , South Korea

Site Status

The Catholic Univ. of Korea Seoul St. Mary's Hospital-cardiology ( Site 3007)

Seoul, , South Korea

Site Status

Hospital Universitario Virgen Macarena ( Site 2352)

Seville, Andalusia, Spain

Site Status

EBA CENTELLES ( Site 2311)

Centelles, Catalonia, Spain

Site Status

Hospital Abente y Lago ( Site 2356)

A Coruña, La Coruna, Spain

Site Status

CHUS - Hospital Clinico Universitario-Cardiology - Clinical Research Unit ( Site 2320)

Santiago de Compostela, La Coruna, Spain

Site Status

HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-Endocrinologia y Nutrición ( Site 2344)

Pozuelo de Alarcón, Madrid, Spain

Site Status

Hospital Universitario Fundacion ALcorcon-Endocrinologia y Nutrición ( Site 2316)

Alcorcón, Madrid, Comunidad de, Spain

Site Status

Vithas Hospital Sevilla-Unidad de Salud Metabólica. Diabetes y Obesidad ( Site 2349)

Castilleja de la Cuesta, Sevilla, Spain

Site Status

HOSPITAL CLINICO DE VALENCIA-CARDIOLOGY ( Site 2321)

Valencia, Valenciana, Comunitat, Spain

Site Status

Hospital Universitario 12 de Octubre-Internal Medicine. Unidad de Ensayos Clínicos ( Site 2319)

Madrid, , Spain

Site Status

Chi Mei Medical Center-Cardiology ( Site 3104)

Tainan City, Tainan, Taiwan

Site Status

Changhua Christian Hospital ( Site 3101)

Changhua, , Taiwan

Site Status

Chang Gung Memorial Hospital at Kaohsiung ( Site 3102)

Kaohsiung City, , Taiwan

Site Status

National Cheng Kung University Hospital ( Site 3107)

Tainan City, , Taiwan

Site Status

National Taiwan University Hospital ( Site 3100)

Taipei, , Taiwan

Site Status

Taipei Medical University Hospital-Cardiology ( Site 3108)

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital ( Site 3106)

Taipei, , Taiwan

Site Status

Hacettepe Universite Hastaneleri ( Site 2500)

Altindağ, Ankara, Turkey (Türkiye)

Site Status

Ege Universitesi Hastanesi-Cardilogy Department ( Site 2502)

Bornova, İzmir, Turkey (Türkiye)

Site Status

Ankara Bilkent Şehir Hastanesi-cardiology ( Site 2501)

Ankara, , Turkey (Türkiye)

Site Status

Eskisehir Osmangazi University-Cardiology ( Site 2510)

Eskişehir, , Turkey (Türkiye)

Site Status

Erciyes Universitesi Tıp Fakultesi Hastaneleri-endocrine ( Site 2522)

Kayseri, , Turkey (Türkiye)

Site Status

Kocaeli Üniversitesi-Cardiology ( Site 2516)

Kocaeli, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina China Colombia Germany Israel Italy Japan Mexico South Africa South Korea Spain Taiwan Turkey (Türkiye)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MK-0616-013

Identifier Type: OTHER

Identifier Source: secondary_id

2022-502777-42-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

U1111-1285-4164

Identifier Type: REGISTRY

Identifier Source: secondary_id

jRCT2031230320

Identifier Type: REGISTRY

Identifier Source: secondary_id

0616-013

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MK-0524B Lipid Study (MK-0524B-063)
NCT00479882 COMPLETED PHASE3